• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by First Light Acquisition Group Inc. (Amendment)

    2/14/24 4:02:35 PM ET
    $FLAG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $FLAG alert in real time by email
    SC 13G/A 1 cldia2_21424.htm 683 CAPITAL MANAGEMENT, LLC cldia2_21424.htm
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 13G
    Under the Securities Exchange Act of 1934
    (Amendment No. 2)*
    Calidi Biotherapeutics, Inc.
    (Name of Issuer)
    Class A Common Stock, par value $0.0001 per share
    (Title of Class of Securities)
    320703200
    (CUSIP Number)
    December 31, 2023
    (Date of Event which Requires Filing of this Statement)
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    [   ] Rule 13d-1(b)
    [X] Rule 13d-1(c)
    [   ] Rule 13d-1(d)
    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see Instructions).
    CUSIP No.: 320703200
           
    1
    NAME OF REPORTING PERSON
    683 Capital Management, LLC
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) [   ]
    (b) [   ]
    3 SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5
    SOLE VOTING POWER
    0
    6
    SHARED VOTING POWER
    675,758
    7
    SOLE DISPOSITIVE POWER
    0
    8
    SHARED DISPOSITIVE POWER
    675,758
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    675,758
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    [   ]
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    1.9%
    12
    TYPE OF REPORTING PERSON
    IA
    CUSIP No.: 320703200
           
    1
    NAME OF REPORTING PERSON
    683 Capital Partners, LP
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) [   ]
    (b) [   ]
    3 SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5
    SOLE VOTING POWER
    0
    6
    SHARED VOTING POWER
    675,758
    7
    SOLE DISPOSITIVE POWER
    0
    8
    SHARED DISPOSITIVE POWER
    675,758
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    675,758
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    [   ]
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    1.9%
    12
    TYPE OF REPORTING PERSON
    PN
    CUSIP No.: 320703200
           
    1
    NAME OF REPORTING PERSON
    Ari Zweiman
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) [   ]
    (b) [   ]
    3 SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    United States of America
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5
    SOLE VOTING POWER
    0
    6
    SHARED VOTING POWER
    675,758
    7
    SOLE DISPOSITIVE POWER
    0
    8
    SHARED DISPOSITIVE POWER
    675,758
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    675,758
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    [   ]
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    1.9%
    12
    TYPE OF REPORTING PERSON
    IN
    CUSIP No.: 320703200
    ITEM 1(a). NAME OF ISSUER:
    Calidi Biotherapeutics, Inc.
    ITEM 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
    11110 Sunset Hills Road #2278, Reston, VA 20190
    ITEM 2(a). NAME OF PERSON FILING:
    683 Capital Management, LLC
    683 Capital Partners, LP
    Ari Zweiman
    ITEM 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
    The principal business address for each of the Reporting Persons is 1700 Broadway, Suite 4200, New York, NY 10019.
    ITEM 2(c). CITIZENSHIP:
    683 Capital Management, LLC is a Delaware limited liability company. 683 Capital Partners, LP is a Delaware limited partnership. Ari Zweiman is a citizen of the United States.

    ITEM 2(d). TITLE OF CLASS OF SECURITIES:
    Class A Common Stock, par value $0.0001 per share (the Common Stock)
    ITEM 2(e). CUSIP NUMBER:
    320703200
    ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SECTION 240.13d-1(b), or 13d-2(b) or (c) CHECK WHETHER THE PERSON FILING IS A:
    (a)
    [ ]
    Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78c);
    (b)
    [ ]
    Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)
    [ ]
    Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)
    [ ]
    Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);
    (e)
    [ ]
    An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E);
    (f)
    [ ]
    An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F);
    (g)
    [ ]
    A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G);
    (h)
    [ ]
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)
    [ ]
    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)
    [ ]
    A non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J);
    (k)
    [ ]
    Group, in accordance with 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with 240.13d1(b)(1)(ii)(J), please specify the type of institution:
    ITEM 4. OWNERSHIP
    (a) Amount beneficially owned:
    As of December 31, 2023, 683 Capital Partners, LP beneficially owned 675,758 shares of Common Stock.

    683 Capital Management, LLC, as the investment manager of 683 Capital Partners, LP, may be deemed to have beneficially owned the 675,758 shares of Common Stock beneficially owned by 683 Capital Partners, LP.

    Ari Zweiman, as the Managing Member of 683 Capital Management, LLC, may be deemed to have beneficially owned the 675,758 shares of Common Stock beneficially owned by 683 Capital Management, LLC.
    (b) Percent of class:
    The following percentage is based on 35,436,381 shares of Common Stock outstanding as of November 10, 2023, as disclosed in the Issuers Quarterly Report on Form 10-Q filed on October 25, 2023.

    As of December 31, 2023, the Reporting Persons may be deemed to have beneficially owned approximately 1.9% of the outstanding shares of Common Stock.
    (c) Number of shares as to which the person has:
    (i) sole power to vote or to direct the vote:
    See Cover Pages Items 5-9.
    (ii) shared power to vote or to direct the vote:
    See Cover Pages Items 5-9.
    (iii) sole power to dispose or direct the disposition of:
    See Cover Pages Items 5-9.
    (iv) shared power to dispose or to direct the disposition of:
    See Cover Pages Items 5-9.
    ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].
    ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:
    Not applicable.
    ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY:
    Not applicable.
    ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:
    See Exhibit A of Schedule 13G filed on October 26, 2021.
    ITEM 9. NOTICE OF DISSOLUTION OF GROUP:
    Not applicable.
    ITEM 10. CERTIFICATION:
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
    CUSIP No.: 320703200
    SIGNATURE
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
    February 14 2024
    683 Capital Management, LLC
    By:
    /s/ Ari Zweiman
    Name:
    Ari Zweiman
    Title:
    Managing Member
    February 14 2024
    683 Capital Partners, LP
    By:
    /s/ Ari Zweiman
    Name:
    Ari Zweiman
    Title:
    Authorized Person
    February 14 2024
    Ari Zweiman
    By:
    /s/Ari Zweiman
    Name:
    Ari Zweiman
    Title:
    Attention — Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).
    Get the next $FLAG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FLAG

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $FLAG
    SEC Filings

    View All

    First Light Acquisition Group Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

    8-K - Calidi Biotherapeutics, Inc. (0001855485) (Filer)

    2/12/24 6:30:32 AM ET
    $FLAG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 424B3 filed by First Light Acquisition Group Inc.

    424B3 - Calidi Biotherapeutics, Inc. (0001855485) (Filer)

    2/12/24 6:32:40 AM ET
    $FLAG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    First Light Acquisition Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure

    8-K - Calidi Biotherapeutics, Inc. (0001855485) (Filer)

    2/7/24 1:06:39 PM ET
    $FLAG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FLAG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Zulueta Alfonso G was granted 5,644 shares, increasing direct ownership by 4% to 133,301 units (SEC Form 4)

    4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)

    1/4/24 7:55:27 PM ET
    $FLAG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Stewart Alan R. was granted 7,282 shares, increasing direct ownership by 15% to 54,655 units (SEC Form 4)

    4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)

    1/4/24 7:52:55 PM ET
    $FLAG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Schoeneck James A was granted 10,625 shares, increasing direct ownership by 62% to 27,872 units (SEC Form 4)

    4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)

    1/4/24 7:51:34 PM ET
    $FLAG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FLAG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Calidi Biotherapeutics Debuts as a Publicly Traded Company Focused on Arming the Immune System to Fight Cancer with a New Generation of Targeted Immunotherapies

    Business combination transaction with First Light Acquisition Group, a special purpose acquisition company, completed on September 12, 2023 Gross proceeds made available to Calidi Biotherapeutics from transaction total approximately $28 million, including funds held in First Light Acquisition Group's trust account before deducting transaction expenses and debt repayments In addition, Calidi secured a forward purchase agreement for up to $10 million with a consortium including Meteora Capital LLC, Great Point Capital LLC, and Funicular Funds, LP and intends to enter into a purchase agreement with Lincoln Park Capital Fund, LLC for up to $50 million; proceeds to extend Calidi's cash runway

    9/13/23 5:50:00 AM ET
    $FLAG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    First Light Acquisition Group Announces NYSE Approval for Listing of Business Combination with Calidi Biotherapeutics and Additional New Capital Commitments

    Business combination transaction with Calidi Biotherapeutics anticipated to be completed on September 12, 2023 Gross proceeds made available to Calidi Biotherapeutics from transaction will total approximately $28 million, including funds held in First Light Acquisition Group's trust account before deducting transaction expenses and debt repayments In addition, Calidi secured a forward purchase agreement for up to $10 million with a consortium including Meteora Capital LLC, Great Point Capital LLC, and Funicular Funds, LP Listed company to be named Calidi Biotherapeutics, Inc. Common stock and warrants approved for listing on the New York Stock Exchange American under the ticker symbols

    9/11/23 4:05:40 PM ET
    $FLAG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FIRST LIGHT ACQUISITION GROUP, INC. Adjourns Special Meeting of Stockholders to August 24, 2023 at 10:30 am ET

    NEW YORK, Aug. 22, 2023 (GLOBE NEWSWIRE) -- First Light Acquisition Group, Inc. (NYSE:FLAG) ("FLAG") today announced that it convened and then adjourned, without conducting any other business, its virtual Special Meeting of Stockholders to August 24, 2023 at 10:30 a.m., Eastern time (the "Special Meeting"). The adjourned Special Meeting will be held via the same live webcast at https://www.cstproxy.com/firstlightacquisition/2023. The Special Meeting is being held to consider and vote on, among other things, the business combination transaction between FLAG and Calidi Biotherapeutics, Inc. ("Calidi"), pursuant to an Agreement and Plan of Merger, dated January 9, 203, as amended, by and amo

    8/22/23 11:41:05 AM ET
    $FLAG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FLAG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by First Light Acquisition Group Inc. (Amendment)

    SC 13G/A - Calidi Biotherapeutics, Inc. (0001855485) (Subject)

    2/14/24 4:02:35 PM ET
    $FLAG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by First Light Acquisition Group Inc. (Amendment)

    SC 13G/A - Calidi Biotherapeutics, Inc. (0001855485) (Subject)

    2/14/24 6:05:50 AM ET
    $FLAG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by First Light Acquisition Group Inc. (Amendment)

    SC 13G/A - Calidi Biotherapeutics, Inc. (0001855485) (Subject)

    2/12/24 5:32:10 PM ET
    $FLAG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care